TY - JOUR
T1 - Hedgehog Pathway Inhibitors
T2 - A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia
AU - Jamieson, Catriona
AU - Martinelli, Giovanni
AU - Papayannidis, Cristina
AU - Cortes, Jorge E.
N1 - Funding Information:
Pfizer provided a formal review of the publication, including for medical accuracy, but the authors had final authority. The experts were not compensated for manuscript preparation. Medical writing support was provided by Anne Marie McGonigal, PhD, of Engage Scientific Solutions, and funded by Pfizer.
Publisher Copyright:
©2020 American Association for Cancer Research.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Targeting Hedgehog (Hh) pathway components, such as Smoothened (SMO), is a developing strategy for the treatment of acute myeloid leukemia (AML) and for overcoming relapsed/refractory forms of this disease. Several SMO inhibitors are in clinical development for the treatment of various tumor types and the results from some clinical trials in AML have been reported. This review will discuss the role of Hh signaling in AML pathogenesis, describe the preclinical and clinical development of Hh pathway inhibitors for the treatment of AML, and examine the current evidence on Hh pathway inhibitor resistance and the implications for treatment selection in AML.
AB - Targeting Hedgehog (Hh) pathway components, such as Smoothened (SMO), is a developing strategy for the treatment of acute myeloid leukemia (AML) and for overcoming relapsed/refractory forms of this disease. Several SMO inhibitors are in clinical development for the treatment of various tumor types and the results from some clinical trials in AML have been reported. This review will discuss the role of Hh signaling in AML pathogenesis, describe the preclinical and clinical development of Hh pathway inhibitors for the treatment of AML, and examine the current evidence on Hh pathway inhibitor resistance and the implications for treatment selection in AML.
UR - http://www.scopus.com/inward/record.url?scp=85101317840&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101317840&partnerID=8YFLogxK
U2 - 10.1158/2643-3230.BCD-20-0007
DO - 10.1158/2643-3230.BCD-20-0007
M3 - Review article
C2 - 34661144
AN - SCOPUS:85101317840
SN - 2643-3230
VL - 1
SP - 134
EP - 145
JO - Blood cancer discovery
JF - Blood cancer discovery
IS - 2
ER -